 Vascular Endothelial Growth Factor Receptor-2
"Vascular Endothelial Growth Factor Receptor-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 200-230-kDa tyrosine kinase receptor for vascular endothelial growth factors found primarily in endothelial and hematopoietic cells and their precursors. VEGFR-2 is important for vascular and hematopoietic development, and mediates almost all endothelial cell responses to VEGF.
| Descriptor ID |
D040301
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.950.200 D12.776.543.750.060.750.200 D12.776.543.750.750.400.910.200
|
| Concept/Terms |
Vascular Endothelial Growth Factor Receptor-2- Vascular Endothelial Growth Factor Receptor-2
- Vascular Endothelial Growth Factor Receptor 2
- Flk-1 Protein
- Flk 1 Protein
- Flk-1 Receptor Tyrosine Kinase
- Flk 1 Receptor Tyrosine Kinase
- KDR Tyrosine Kinase
- Tyrosine Kinase, KDR
- VEGF Receptor Flk-1
- Flk-1, VEGF Receptor
- VEGF Receptor Flk 1
- VEGF Receptor KDR
- KDR, VEGF Receptor
- VEGFR-2
- Fetal Liver Kinase-1
- Fetal Liver Kinase 1
- Kinase Insert Domain Receptor
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor Receptor-2".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor Receptor-2".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor Receptor-2" by people in this website by year, and whether "Vascular Endothelial Growth Factor Receptor-2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 3 | 2 | 5 | | 2005 | 1 | 0 | 1 | | 2007 | 2 | 0 | 2 | | 2008 | 1 | 3 | 4 | | 2009 | 6 | 2 | 8 | | 2011 | 2 | 3 | 5 | | 2012 | 2 | 0 | 2 | | 2013 | 1 | 1 | 2 | | 2014 | 4 | 0 | 4 | | 2015 | 1 | 1 | 2 | | 2016 | 2 | 1 | 3 | | 2017 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 | | 2020 | 1 | 1 | 2 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor Receptor-2" by people in Profiles.
-
Taylor GS, Shaw A, Smith K, Capper TE, Scragg JH, Cronin M, Bashir A, Flatt A, Campbell MD, Stevenson EJ, Shaw JA, Ross M, West DJ. Type 1 diabetes patients increase CXCR4+ and CXCR7+ haematopoietic and endothelial progenitor cells with exercise, but the response is attenuated. Sci Rep. 2021 07 15; 11(1):14502.
-
Zhai S, Zhang XF, Lu F, Chen WG, He X, Zhang CF, Wang CZ, Yuan CS. Chinese medicine GeGen-DanShen extract protects from myocardial ischemic injury through promoting angiogenesis via up-regulation of VEGF/VEGFR2 signaling pathway. J Ethnopharmacol. 2021 Mar 01; 267:113475.
-
Mehta V, Pang KL, Rozbesky D, Nather K, Keen A, Lachowski D, Kong Y, Karia D, Ameismeier M, Huang J, Fang Y, Del Rio Hernandez A, Reader JS, Jones EY, Tzima E. The guidance receptor plexin D1 is a mechanosensor in endothelial cells. Nature. 2020 02; 578(7794):290-295.
-
Yokomizo H, Maeda Y, Park K, Clermont AC, Hernandez SL, Fickweiler W, Li Q, Wang CH, Paniagua SM, Simao F, Ishikado A, Sun B, Wu IH, Katagiri S, Pober DM, Tinsley LJ, Avery RL, Feener EP, Kern TS, Keenan HA, Aiello LP, Sun JK, King GL. Retinol binding protein 3 is increased in the retina of patients with diabetes resistant to diabetic retinopathy. Sci Transl Med. 2019 07 03; 11(499).
-
Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clin Lung Cancer. 2018 05; 19(3):213-220.e4.
-
Maron SB, Catenacci DVT. Update on Gastroesophageal Adenocarcinoma Targeted Therapies. Hematol Oncol Clin North Am. 2017 06; 31(3):511-527.
-
Suzuki N, Hazama S, Iguchi H, Uesugi K, Tanaka H, Hirakawa K, Aruga A, Hatori T, Ishizaki H, Umeda Y, Fujiwara T, Ikemoto T, Shimada M, Yoshimatsu K, Shimizu R, Hayashi H, Sakata K, Takenouchi H, Matsui H, Shindo Y, Iida M, Koki Y, Arima H, Furukawa H, Ueno T, Yoshino S, Nakamura Y, Oka M, Nagano H. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci. 2017 Jan; 108(1):73-80.
-
Gawlak G, Son S, Tian Y, O'Donnell JJ, Birukov KG, Birukova AA. Chronic high-magnitude cyclic stretch stimulates EC inflammatory response via VEGF receptor 2-dependent mechanism. Am J Physiol Lung Cell Mol Physiol. 2016 06 01; 310(11):L1062-70.
-
Tian Y, Gawlak G, O'Donnell JJ, Birukova AA, Birukov KG. Activation of Vascular Endothelial Growth Factor (VEGF) Receptor 2 Mediates Endothelial Permeability Caused by Cyclic Stretch. J Biol Chem. 2016 May 06; 291(19):10032-45.
-
O'Donnell PH, Karovic S, Karrison TG, Janisch L, Levine MR, Harris PJ, Polite BN, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|